



Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office	Docket No. SGEN-0051	Application No. 10/522,911
	Applicant Peter D. Senter, Svetlana O. Doronina and Brian E. Toki	
	Filing Date July 7, 2005	Group 1654
	Confirmation 7034	

U. S. PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Name	Class	Subclass
	1	3,445,518	05/1969	Shavel et al.	260	570.8
	2	4,753,894	06/1998	Frankel et al.	436	548
	3	4,943,628	07/1990	Rosen et al.	530	326
	4	5,122,368	06/1992	Greenfield	424	85.1
	5	5,165,923	11/1992	Thorpe	424	999.999
	6	5,169,774	12/1992	Frankel et al.	436	240.27
	7	5,286,637	02/1994	Veronese et al.	435	183
	8	5,585,089	12/1996	Queen	424	130.1
	9	5,629,197	05/1997	Ring et al.	435	240.27
	10	5,708,146	01/1998	Willner	530	387
	11	5,714,586	02/1998	Kunstmann et al.	530	391.7
	12	5,821,337	10/1998	Carter et al.	530	387.3
	13	5,965,537	10/1999	Ritter	514	17
	14	6,033,876	03/2000	Lemke	435	69.6
	15	6,048,720	04/2000	Dalborg et al.	435	219
	16	6,054,297	04/2000	Carter et al.	435	69.6
	17	6,054,561	04/2000	Ring	530	388.1
	18	6,143,721	11/2000	Janssen	514	16
	19	6,214,345	04/2001	Firestone et al.	424	178.1
	20	6,323,315	11/2001	Pettit et al.	530	330
	21	6,342,219	01/2002	Thorpe	424	130.1
	22	6,407,213	06/2002	Carter et al.	530	387.3

EXAMINER	DATE CONSIDERED
-----------------	------------------------

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office	Docket No. SGEN-0051	Application No. 10/522,911
	Applicant Peter D. Senter, Svetlana O. Doronina and Brian E. Toki	
	Filing Date July 7, 2005	Group 1654
	Confirmation 7034	

U. S. PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Name	Class	Subclass
	23	6,569,834	05/2003	Pettit et al.	514	18
	24	6,620,911	09/2003	Pettit	517	17
	25	6,639,055	10/2003	Carter et al.	530	350
	26	6,884,869	04/2005	Senter et al.	514	17
	27	6,913,748	07/2005	Widdison	424	1.49
	28	7,090,843	08/2006	Francisco	424	143.1
	29	7,091,186	08/2006	Senter et al.	514	27
	30	7,097,840	08/2006	Erickson et al.	424	178.1
	31	7,098,305	08/2006	Senter et al.	514	17
	32	7,098,308	08/2006	Senter et al.	514	17
	33	2003/0083263	05/2003	Doronina et al.	514	17
	34	2003/0130189	07/2003	Senter et al.	514	12
	35	2004/0018194	01/2004	Francisco et al.	424	133.1
	36	2004/0096392	05/2004	Bhaskar et al.	424	1.11
	37	2004/0141983	07/2004	Law et al.	424	178.1
	38	2004/0197325	10/2004	Law et al.	424	131.1
	39	2004/0235068	11/2004	Levinson	435	7.23
	40	2005/0014687	01/2005	Anderson et al.	514	12
	41	2005/0084449	04/2005	Landes	424	1.49
	42	2005/0106644	05/2005	Caims et al.	424	133.1
	43	2005/0107595	05/2005	Caims et al.	424	133.1
	44	2005/0123536	06/2005	Law et al.	424	133.1

EXAMINER	DATE CONSIDERED
-----------------	------------------------

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office	Docket No. SGEN-0051	Application No. 10/522,911
	Applicant Peter D. Senter, Svetlana O. Doronina and Brian E. Toki	
	Filing Date July 7, 2005	Group 1654
	Confirmation 7034	

U. S. PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Name	Class	Subclass
	45	2005/0180972	08/2005	Wahl et al.	424	133.1
	46	2005/0238650	10/2005	Crowley et al.	424	178.1
	47	2005/0238649	10/2005	Doronina	514	17
	48	2005/0260212	11/2005	Zhang et al.	424	178.1
	49	2005/0256030	11/2005	Feng	514	2
	50	2005/0272665	12/2005	Schmid et al.	548	573
	51	2006/0074008	04/2006	Senter et al.	514	2
	52	2006/0073152	04/2006	Dennis	424	155.1
	53	2006/0128970	06/2006	Bliss et al.	548	400
	54	2006/0233794	10/2006	Che-Leung Law	424	155.1
	55	2007/0092940	04/2007	Eigenbrot	435	69.1
	56	2007/0098715	05/2007	Ettenberg et al.	424	143.1
	57	2007/0160617	07/2007	Ma et al.	424	155.1
	58	2007/0258987	11/2007	Francisco	424	181.1

EXAMINER	DATE CONSIDERED
-----------------	------------------------

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office	Docket No. SGEN-0051	Application No. 10/522,911
	Applicant Peter D. Senter, Svetlana O. Doronina and Brian E. Toki	
	Filing Date July 7, 2005	Group 1654
	Confirmation 7034	

FOREIGN PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Country	Translation	
					YES	NO
	59	CA 2114156	04/1994	CA		
	60	JP 06234790	08/1994	JP	Abstract Only	
	61	JP 09077791	03/1997	JP	Abstract Only	
	62	WO 93/03054	02/1993	PCT	Abstract Only	
	63	WO 95/09864	04/1995	PCT	Abstract Only	
	64	WO 96/22384	07/1996	PCT		
	65	WO 99/35164	07/1999	PCT		
	66	WO 01/18032	03/2001	PCT		
	67	WO 02/088172	11/2002	PCT		
	68	WO 03/008378	01/2003	PCT		
	69	WO 03/034903	05/2003	PCT		
	70	WO 03/043583	05/2003	PCT		
	71	WO 04/32828	04/2004	PCT		
	72	WO 05/084390	09/2005	PCT		
	73	WO 2006/071441	07/2006	PCT		
	74	WO 2006/083936	08/2006	PCT		
	75	WO 2007/030642	03/2007	PCT		
	76	WO 2007/070538	06/2007	PCT		
	77	WO 2007/059082	05/2007	PCT		

EXAMINER	DATE CONSIDERED
-----------------	------------------------

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office				Docket No. SGEN-0051		Application No. 10/522,911	
				Applicant Peter D. Senter, Svetlana O. Doronina and Brian E. Toki			
				Filing Date July 7, 2005		Group 1654	
				Confirmation 7034			
FOREIGN PATENT DOCUMENTS							
Examiner Initial		Document No.	Date	Country	Translation		
					YES	NO	
	78	WO 2007/109567	09/2007	PCT			
	79	WO 2007/062138	05/2007	PCT			

EXAMINER	DATE CONSIDERED
-----------------	------------------------

Form PTO-1449 Modified		Docket No. SGEN-0051	Application No. 10/522,911
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant Peter D. Senter, Svetlana O. Doronina and Brian E. Toki	
U.S. Department of Commerce Patent and Trademark Office		Filing Date July 7, 2005	Group 1654
		Confirmation 7034	
NON-PATENT DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	80	LAW et al., "CD70 is expressed on renal cell carcinoma and is a potential target for tumor cell elimination by antibody-drug conjugates," <i>Proceedings of the AACR</i> , volume 45, Abstract # 625, 2004	
	81	Hamblett et al., "Effect of drug loading on the pharmacology, pharmacokinetics, and toxicity of an anti-CD30 antibody-drug conjugate," <i>Proceedings of the AACR</i> , volume 45, Abstract # 624, 2004	
	82	Senter et al., "Immunoconjugates comprised of drugs with impaired cellular permeability: A new approach to targeted therapy," <i>Proceedings of the AACR</i> , volume 45, Abstract # 623, 2004	
	83	PRESS RELEASE, "Seattle Genetics, Inc. (SGEN) To Present Advances in Preclinical Research At American Cancer Research Annual Meeting," downloaded from internet on August 31, 2004	
	84	Afar et al., "Preclinical validation of anti-TMEFF2-auristatin E-conjugated antibodies in the treatment of prostate cancer," <i>Molecular Cancer Therapeutics</i> , 2004 , 921-932	
	85	Bhaskar et al., "E-Selectin Up-Regulation Allows for Targeted Drug Delivery in Prostate Cancer," <i>Cancer Research</i> , 2003 , 63, 6387-6394	
	86	Doronina et al., "Development of potent monoclonal antibody auristatin conjugates for cancer therapy," <i>Nature Biotechnology</i> , 2003 , 21(7), 778-784	
	87	Doronina et al., "Errata and Corrigenda," <i>Nature Biotechnology</i> , 2003 , 21(8), 941	
	88	Falini et al., "Response of refractory Hodgkin's disease to monoclonal anti-CD30 immunotoxin," <i>The Lancet</i> , 1992 , 339, 1195-1196	
	89	Fransico et al., "cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity," <i>Blood</i> , 2003 , 102(4), 1458-1465	
	90	Frisch et al., "Synthesis of Short Polyoxyethylene-Based Heterobifunctional Cross-Linking Reagents. Application to the Coupling of Peptides to Liposomes," <i>Bioconjugate Chem.</i> , 1996 , 7, 180-186	
EXAMINER		DATE CONSIDERED	

Form PTO-1449 Modified		Docket No. SGEN-0051	Application No. 10/522,911
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant Peter D. Senter, Svetlana O. Doronina and Brian E. Toki	
U.S. Department of Commerce Patent and Trademark Office		Filing Date July 7, 2005	Group 1654
		Confirmation 7034	
NON-PATENT DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	91	Gaertner et al., "Site-Specific Attachment of Functionalized Poly(ethylene glycol) to the Amino Terminus of Proteins," <i>Bioconjugate Chem.</i> , 1996 , 7, 38-44	
	92	Genet, J.P., "Recent studies on asymmetric hydrogenation. New catalysts and synthetic applications in organic synthesis," <i>Pure Appl. Chem.</i> , 2002 , 74(1), 77-83	
	93	Aherne et al., "Antitumour evaluation of dolastatins 10 and 15 and their measurement in plasma by radioimmunoassay," <i>Cancer Chemother. Pharmacol.</i> , 1996 , 38, 225-232	
	94	Engert et al., "Evaluation of Ricin A Chain-containing Immunotoxins Directed against the CD30 Antigen as Potential Reagents for the Treatment of Hodgkin's Disease," <i>Cancer Research</i> , 1990 , 50, 84-88	
	95	King et al., "Monoclonal Antibody Conjugates of Doxorubicin Prepared with Branched Linkers: A Novel Method for Increasing the Potency of Doxorubicin Immunoconjugates," <i>Bioconjugate Chem.</i> , 1999 , 10, 279-288	
	96	King et al., "Monoclonal Antibody Conjugates of Doxorubicin with Branched Peptide Linkers: Inhibition of Aggregation by Methoxytriethyleneglycol Chains," <i>J. Med. Chem.</i> , 2002 , 45, 4336-4343	
	97	Kline et al., "Novel Antitumor Prodrugs Designed for Activation by Matrix Metalloproteinases-2 and -9," <i>Molecular Pharmaceutics</i> , 2003 , 1(1), 9-22	
	98	Klussman et al., "Secondary mAb-vcMMAE Conjugates Are Highly Sensitive Reporters of Antibody Internalization via the Lysosome Pathway," <i>Bioconjugate Chem.</i> , 2004 , 15, 765-773	
	99	Mao et al., "EphB2 as a Therapeutic Antibody Drugs target for the Treatment of Colorectal Cancer," <i>Cancer Research</i> , 2004 , 64, 781-788	
	100	May et al., "Evaluation of Ricin a Chain-Containing Immunotoxins Directed Against Different Epitopes On The δ -Chain of Cell Surface-Associated IgD on Murine B Cells," <i>The Journal of Immunology</i> , 1990 , 144(9), 3637-3642	

EXAMINER	DATE CONSIDERED
----------	-----------------

Form PTO-1449 Modified		Docket No. SGEN-0051	Application No. 10/522,911
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant Peter D. Senter, Svetlana O. Doronina and Brian E. Toki	
U.S. Department of Commerce Patent and Trademark Office		Filing Date July 7, 2005	Group 1654
		Confirmation 7034	
NON-PATENT DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	101	Natsume et al., "Characterization of the Interaction of TZT-1027, a Potent Antitumor Agent, with Tubulin," <i>Jpn. J. Cancer Res.</i> , 2000 , 91, 737-747	
	102	Pettit et al., "Specific Activities of Dolastatin 10 and Peptide Derivatives against <i>Cryptococcus neoformans</i> ," <i>Antimicrobial Agents and Chemotherapy</i> , 1998 , 42(11), 2961-2965	
	103	Pettit et al., "A Cobalt-Phosphine Complex Directed Reformatsky Approach to a stereospecific Synthesis of the Dolastatin 10 Unit Dolaproine (DAP)," <i>J. Org. Chem.</i> , 2001 , 66, 8640-8642	
	104	Press et al., "Ricin A-Chain Containing Immunotoxins Directed Against Different Epitopes on the CD2 Molecule Differ In Their Ability to Kill Normal and Malignant T Cells," <i>The Journal of Immunology</i> , 1988 , 141(12), 4410-4417	
	105	Meyer et al., "Chapter 23. Recent Advances In Antibody Drug Conjugates for Cancer Therapy," <i>Annual Reports in Medicinal Chemistry</i> , 2003 , 229-237	
	106	Schnell et al., "Development Of New Ricin A-Chain Immunotoxins With Potent Anti-Tumor effects Against Human Hodgkin Cells <i>In Vitro</i> And Disseminated Hodgkin Tumors in Scid Mice Using High-Affinity Monoclonal Antibodies Directed Against The CD30 Antigen," <i>Int. J. Cancer</i> , 1995 , 63, 238-244	
	107	Schöffski et al., "Phase I and pharmacokinetic study of TZT-1027, a novel synthetic dolastatin 10 derivative, administered as a 1-hour intravenous infusion every 3 weeks in patients with advanced refractory cancer," <i>Annals of Oncology</i> , 2004 , 15, 671-679	
	108	Doronina et al., "Immunoconjugates comprised of drugs with impaired cellular permeability: A new approach to targeted therapy," <i>SciFinder</i> , 2005 , 10 pages	
	109	Thornber, C.W., "Isoterism and Molecular Modification in Drug Design," <i>Imperial Chemical Industries Limited</i> , downloaded 2007 , 563-580	
	110	Toki et al., "Protease-Mediated Fragmentation of <i>p</i> -Amidobenzyl Ethers: A New Strategy for the Activation of Anticancer Prodrugs," <i>J. Org. Chem.</i> , 2002 , 67, 1866-1872	

EXAMINER	DATE CONSIDERED
----------	-----------------

Form PTO-1449 Modified		Docket No. SGEN-0051	Application No. 10/522,911
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant Peter D. Senter, Svetlana O. Doronina and Brian E. Toki	
U.S. Department of Commerce Patent and Trademark Office		Filing Date July 7, 2005	Group 1654
		Confirmation 7034	
NON-PATENT DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	111	Trail et al., "Cure of Xenografted Human Carcinomas by BR96-Doxorubicin Immunoconjugates," <i>Science</i> , 1993, 261, 212-215	
	112	Trail et al., "Effect of Linker Variation on the Stability, Potency, and Efficacy of Carcinoma-reactive BR64-Doxorubicin Immunoconjugates," <i>Cancer Research</i> , 1997, 57, 100-105	
	113	Tsutsumi et al., "Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38(LMB-2) improves Antitumor activity and reduces animal toxicity and immunogenicity," <i>PNAS</i> , 2000, 97(15), 8548-8553	
	114	Vippagunta et al., "Crystalline solids," <i>Advanced Drug Delivery Reviews</i> , 2001, 48, 3-26	
	115	Woyke et al., "In Vitro Activities and Postantifungal Effects on the Potent Dolastatin 10 Derivative Auristatin PHE," <i>Antimicrobial Agents and Chemotherapy</i> , 2001, 45(12), 3580-3584	
	116	Mohammad et al., "An Orthotopic Model of Human Pancreatic Cancer in Severe Combined Immunodeficient Mice: Potential Application for Preclinical Studies ¹ ," <i>Clinical Cancer Research</i> , 1998, 4, 887-894	
	117	Alley et al., "Controlling the location of drug attachment in antibody-drug conjugates," <i>Proceedings of the AACR</i> , 2004, 45, Abstract #627	
	118	Carter., "Improving the Efficacy of Antibody-Based Cancer Therapies," <i>Nature Reviews</i> , 1989, 1, 118-129	
	119	Dillman., "Monoclonal Antibodies for Treating Cancer," <i>Annals of Internal Medicine</i> , 1989, 11.1, 592-603	
	120	Doronina et al., "Enhanced Activity of Monomethylauristatin F through Monoclonal Antibody Delivery: Effects of Linker Technology on Efficacy and Toxicity," <i>Bioconjugate Chem.</i> , 2006, 17, 114-124	
	121	Emery et al., "Humanized monoclonal antibodies for therapeutic applications," <i>Exp. Opin. Invest. Drugs</i> , 1994, 3(3), 241-251	
EXAMINER		DATE CONSIDERED	

Form PTO-1449 Modified		Docket No. SGEN-0051	Application No. 10/522,911
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant Peter D. Senter, Svetlana O. Doronina and Brian E. Toki	
U.S. Department of Commerce Patent and Trademark Office		Filing Date July 7, 2005	Group 1654
		Confirmation 7034	
NON-PATENT DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	122	Inada et al., "Modification of Proteins with Polyethylene Glycol Derivatives," <i>Methods Enzymology</i> , 1994 , 242, 65-90	
	123	Pettit et al., "The Absolute Configuration and Synthesis of Natual (-) -Dolastin 10," <i>J. Am. Chem. Soc.</i> , 1989 , 111, 5463-5465	
	124	Woyke et al., "Effects of auristatin PHE on micortube integrity and nuclear localization in <i>Cryptococcus neoformans</i> ," <i>Antimicrobial Agents and Chemotherapy</i> , 2003 , 46(12), 3802-3808	
	125	In the United States Patent and Trademark Office: Non-Final Rejection Office Action Summary of Application 10/983,340, Dated 10/04/2007, 17 pages	
	126	In the United States Patent and Trademark Office: Non-Final Rejection Office Action Summary of Application 10/447,257, Dated 04/19/2007, 18 pages	

EXAMINER	DATE CONSIDERED
-----------------	------------------------